TTR and cardiac amyloidosis: Moreover, for transthyretin amyloid cardiomyopathy, tafamidis could significantly decrease all-cause death or heart transplantation and endpoint (all-cause death, hospitalizations, heart failure exacerbations, heart transplant, and heart assist device implantation).